Actuate Therapeutics (ACTU) vs Tvardi Therapeutics (TVRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Actuate Therapeutics (ACTU) has outperformed Tvardi Therapeutics (TVRD) over the past year, losing 92.5% versus a loss of 97.6%. Actuate Therapeutics is the larger company by market cap ($14.7 million vs $13.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | TVRD |
|---|---|---|
| Share price | $0.6102 | $1.03 |
| Market cap | $14.65M | $13.74M |
| 1-day change | -10.13% | -4.63% |
| YTD return | -90.03% | -76.05% |
| 1-year return | -92.46% | -97.60% |
| 5-year return | — | -99.78% |
| EPS (TTM) | $-0.87 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.49 | $43.65 |
| 52-week low | $0.604 | $0.93 |
| Distance from 52-week high | -92.81% | -97.64% |
| Analyst consensus | none | buy |
| Avg. price target upside | +1814.13% | +798.06% |
| Average volume | 386.51K | 424.45K |
| Shares outstanding | 24.01M | 13.34M |
| Employees | 12 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Tvardi Therapeutics
TVRD stock →Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
ACTU vs TVRD FAQ
Which is bigger, Actuate Therapeutics or Tvardi Therapeutics?
Actuate Therapeutics (ACTU) is larger, with a market capitalization of $14.65M compared with $13.74M for Tvardi Therapeutics (TVRD).
Which stock has performed better over the past year, ACTU or TVRD?
ACTU returned -92.46% over the past 12 months, compared with -97.60% for TVRD (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and Tvardi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.